KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Enterprise Value (2019 - 2025)

Royalty Pharma's Enterprise Value history spans 7 years, with the latest figure at $2.6 billion for Q4 2025.

  • For Q4 2025, Enterprise Value rose 7.97% year-over-year to $2.6 billion; the TTM value through Dec 2025 reached $2.6 billion, up 7.97%, while the annual FY2025 figure was $2.6 billion, 7.97% up from the prior year.
  • Enterprise Value for Q4 2025 was $2.6 billion at Royalty Pharma, up from $2.3 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at $4.2 billion in Q1 2021 and bottomed at $1.4 billion in Q2 2023.
  • The 5-year median for Enterprise Value is $2.5 billion (2023), against an average of $2.5 billion.
  • The largest annual shift saw Enterprise Value soared 4603.54% in 2021 before it tumbled 44.83% in 2022.
  • A 5-year view of Enterprise Value shows it stood at $2.9 billion in 2021, then decreased by 23.73% to $2.2 billion in 2022, then soared by 40.15% to $3.1 billion in 2023, then fell by 21.35% to $2.4 billion in 2024, then rose by 7.97% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Enterprise Value are $2.6 billion (Q4 2025), $2.3 billion (Q3 2025), and $2.5 billion (Q2 2025).